MEI Pharma, Inc.
MEIP
$2.05
$0.010.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -292.59% | -213.22% | 155.84% | 169.06% | 163.69% |
| Total Depreciation and Amortization | 57.77% | 77.54% | -0.78% | -4.56% | 0.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 198.89% | 288.57% | 299.54% | -13.16% | 160.46% |
| Change in Net Operating Assets | 85.08% | 87.71% | -237.82% | -215.74% | -231.18% |
| Cash from Operations | 31.97% | 22.71% | 3.83% | 22.77% | 13.87% |
| Capital Expenditure | 100.00% | -125.00% | 80.00% | 86.27% | 90.00% |
| Sale of Property, Plant, and Equipment | 176.92% | -- | -- | -200.00% | -200.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.03% | 31.18% | -8.52% | -10.36% | -1.66% |
| Cash from Investing | -6.93% | 31.10% | -8.47% | -9.95% | -1.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.22% | -- | -- | -58,400.00% | -58,400.00% |
| Cash from Financing | 98.22% | -- | -29,570.00% | -58,200.00% | -3,529.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 423.26% | 131.73% | -1,232.16% | -180.17% | -251.47% |